Facebook Twitter
Search

GLP1-RA Meets MS: Why, How, What’s Next

Presented by 

Daniel Reich, MD, PhD

Activity Overview

Year

2026

CREDIT HOURS

2.0

CREDIT/S AVAILABLE

AAPA, ACPE, ANCC, APA, ASWB, CME, RD, IPCE, Certificate of Completion

Level of Information

Intermediate

Duration

Course Duration: 1h38m

Track/s

Categories 2026, Complimentary to CMSC Members, MS Management
$70.00
  • Duration
    1 hour38 minutes
  • Last Updated
    August 19, 2026

About This Activity

This course provides a comprehensive exploration of GLP-1 receptor agonists (GLP-1 RAs), from their historical development and mechanistic foundations to emerging applications in multiple sclerosis (MS) and practical clinical experience. Participants will gain an understanding of how GLP-1 RAs function, their potential neuroprotective and immunomodulatory effects, and the current state of preclinical and clinical research in MS. Real-world insights from prescribing GLP-1 RAs in MS patients will be shared, including observed outcomes, patient selection considerations, and strategies for integration into practice. By connecting basic science, translational research, and clinical experience, this course equips participants with the knowledge to critically evaluate the evolving role of GLP-1 RAs and apply these insights thoughtfully in MS care.

Target Audience

  • This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, psychologists, social workers, rehabilitation specialists, dietitians, researchers, advocates, and other members of the healthcare team involved in the management of patients with MS.

Learning Objectives

  • Compare MS models of care in order to support the provision of team-based, comprehensive care via the most appropriate model for a given practice setting that appropriately incorporates roles and responsibilities of clinicians and ensures the delivery of evidence-based MS care.
  • Summarize methods to monitor treatment outcomes including patient self-report, automated self-assessment, data from wearable devices, clinician reported outcomes, imaging, and biomarkers in order to optimize their utilization in clinical practice and research.
  • Identify assessment techniques to isolate those factors that affect the complex pathology of MS and related neuroimmune disorders and differentiate between these disease processes and their manifestations and course.
  • Analyze common symptoms of MS and related disorders and their appropriate pharmacologic and non-pharmacologic interventions in order to develop strategies designed to maximize function and quality of life.

Course Content

From Discovery to Therapy: The Evolution of GLP-1 Receptor Agonists

  • From Discovery to Therapy: The Evolution of GLP-1 Receptor Agonists
    26:48
  • GLP-1 Receptor Agonists in Multiple Sclerosis: Mechanistic Rationale, Ongoing Research, and Prospective Applications
    22:11
  • The GLP-1 Receptor Agonist Era in MS Care: How to Support Your Patients
    48:31